Advancements of nanoscale drug formulations for combination treatment of colorectal cancer

被引:1
作者
Li, Liqi [1 ]
Chen, Maohua [2 ]
Reis, Rui L. [3 ,4 ]
Kundu, Subhas C. [3 ,4 ]
Xiao, Bo [5 ]
Shi, Xiaoxiao [6 ]
机构
[1] Army Med Univ, Xinqiao Hosp, Dept Gen Surg, Chongqing 400037, Peoples R China
[2] Army Med Univ, Xinqiao Hosp, Dept Pharm, Chongqing 400037, Peoples R China
[3] Univ Minho, Res Inst Biomat Biodegradables & Biomimet I3Bs, Headquarters European Inst Excellence Tissue Engn, Res Grp 3Bs, P-4805017 Guimaraes, Portugal
[4] ICVS 3Bs PT Government Assoc Lab, Guimara, Portugal
[5] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Personalized Drug Therapy Key Lab Sichuan Prov, Dept Pharm,Sch Med, Chengdu 610054, Peoples R China
[6] Southwest Univ, Coll Sericulture Text & Biomass Sci, State Key Lab Resource Insects, Chongqing 400715, Peoples R China
关键词
Nanomedicine; Colorectal cancer; Drug delivery; Combination therapy; Chemotherapy; CO-DELIVERY; GENE-MUTATIONS; NANOPARTICLES; THERAPY; LIPOSOMES; 5-FLUOROURACIL; PHOTOTHERAPY; DOXORUBICIN; EXPRESSION; CODELIVERY;
D O I
10.1016/j.ijpharm.2025.125508
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combination chemotherapy is widely utilized in treating colorectal cancer (CRC), particularly for patients who are ineligible for surgery or those with metastatic CRC (mCRC). While this therapeutic method has demonstrated efficacy in managing CRC and mCRC, its broader clinical application is limited due to the unique physical properties, mechanisms of action, and pharmacokinetics of different chemotherapeutic drugs. Consequently, achieving satisfactory treatment outcomes proves to be challenging. Nanotechnology has given rise to innovative drug systems that are precise, controllable, and highly efficient in drug delivery. These nanoscale drug delivery systems can integrate the advantageous aspects of various therapeutic modalities, including chemotherapy, gene therapy, and immunotherapy. This review aims to explain the application of nano-drug delivery system in the treatment of colorectal cancer. Through its unique physical/chemical properties and biological functions, it can solve the limitations of traditional therapy and achieve more accurate, efficient and safe treatment. The advantages/disadvantages, physical and chemical characteristics of various drug delivery systems are described in detail, and suggestions on selecting reasonable NDDSs according to different drug combination methods are given to achieve the best therapeutic effect. This review paper presents an exhaustive summary of the diverse range of drugs utilized in chemotherapy, in addition to outlining strategies for effectively integrating chemotherapy with other treatment modalities. Furthermore, it delves into the principle of selecting carriers for various drug combinations.
引用
收藏
页数:22
相关论文
共 174 条
[1]   Microsatellite instability in colorectal cancer: An analysis of the National Cancer Database. [J].
Abushalha, Kamelah ;
Abulaimoun, Sawsan ;
Aurit, Sarah J. ;
Jenkins, Erin ;
Silberstein, Peter T. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[2]   Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TIGAR translation in colorectal cancer [J].
Ahmad, Rehan ;
Alam, Maroof ;
Hasegawa, Masanori ;
Uchida, Yasumitsu ;
Al-Obaid, Omar ;
Kharbanda, Surender ;
Kufe, Donald .
MOLECULAR CANCER, 2017, 16
[3]   Synergistic Antitumor Potency of a Self-Assembling Cyclodextrin Nanoplex for the Co-Delivery of 5-Fluorouracil and Interleukin-2 in the Treatment of Colorectal Cancer [J].
Akkin, Safiye ;
Varan, Gamze ;
Isik, Anil ;
Goksen, Sibel ;
Karakoc, Elif ;
Malanga, Milo ;
Esendagli, Gunes ;
Korkusuz, Petek ;
Bilensoy, Erem .
PHARMACEUTICS, 2023, 15 (02)
[4]   Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer. [J].
Aldubayan, Saud H. ;
Giannakis, Marios ;
Moore, Nathanael ;
Mu, Xinmeng Jasmine ;
Han, G. Celine ;
Nishihara, Reiko ;
Qian, Zhi Rong ;
Liu, Li ;
Ogino, Shuji ;
Garraway, Levi A. ;
Fuchs, Charles S. ;
Van Allen, Eliezer Mendel .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5]   What function of nanoparticles is the primary factor for their hyper-toxicity? [J].
Ali, Mohd .
ADVANCES IN COLLOID AND INTERFACE SCIENCE, 2023, 314
[6]   Colorectal cancer and absolute risks [J].
不详 .
GUT, 2021, 70 (11) :2215-2216
[7]   Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). [J].
Argiles, Guillem ;
Jungels, Christiane ;
Garcia-Carbonero, Rocio ;
Garcia, Marc Diez ;
Bendell, Johanna C. ;
Tabernero, Josep ;
Bekradda, Mohamed ;
van Bueren, Jeroen Lammerts ;
Bol, Kees ;
Stalbovskaya, Viktoriya ;
Fatrai, Szabolcs ;
Brinkman, Arjen ;
Wasserman, Ernesto ;
Hollebecque, Antoine .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8]   Identification of microRNAs that target PD-L1 in mismatch repair-deficient colorectal cancer. [J].
Ashizawa, Mai ;
Okayama, Hirokazu ;
Ishigame, Teruhide ;
Mimura, Kousaku ;
Kono, Koji .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[9]   Polymeric Nanoparticles for Drug Delivery [J].
Beach, Maximilian A. ;
Nayanathara, Umeka ;
Gao, Yanting ;
Zhang, Changhe ;
Xiong, Yijun ;
Wang, Yufu ;
Such, Georgina K. .
CHEMICAL REVIEWS, 2024, 124 (09) :5505-5616
[10]   Prognostic impact of PD-L1 and PD-1 expression by primary tumor location in colorectal cancer. [J].
Berntsson, Jonna ;
Larsson, Anna ;
Nodin, Bjorn ;
Eberhard, Jakob ;
Jirstrom, Karin .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)